Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)
NCT05584930 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2024-12-30
Summary
Febrile aplasia is a common occurrence in children/adults treated with chemotherapy for malignant blood diseases or solid cancers.
This acquired deficiency of immunity mainly causes susceptibility to bacterial and fungal infections, pathogens normally recognized by specific receptors of innate immunity (Pattern Recognition Receptor, PRR).
Thus, the febrile episodes in the context of post-chemotherapy neutropenia can be bacterial or fungal etiology, but can also frequently be related to viral infections, toxic phenomena or other etiologies. In the absence of a discriminating marker, treatment for all these children is based on early, broad-spectrum antibiotic therapy in hospital. Septic shock or even death by refractory septic shock remain, even if they are rare, real complications in pediatric oncology, requiring discriminatory markers for effective management, While trying to reduce the number and duration of hospitalizations for children at low risk for severe febrile aplasia.
It is therefore necessary to identify other markers allowing the earliest possible classification of episodes of febrile aplasia.
A previous study, conducted by our team, PTX3 and febrile aplasia, studied pentraxin 3 (PTX3), a soluble PRR of the pentraxin family that plays a key role in immune surveillance against pathogens. Preliminary results obtained from samples from a cohort of patients treated in adult hematology and pediatric onco-hematology support a prognostic character of PTX3 in the severity of aplasia, with higher elevations of serum protein during episodes of severe sepsis or septic shock (ongoing analyses and interpretations for the adult population). The available data to date on the pediatric cohort are insufficient to conclude on the value of using PTX3. The investigators therefore wish to create a new paediatric cohort, in order to evaluate the PTX3 levels for the paediatric population and also to perform the assay of a new marker, clusterin.
Clusterin (CLU) is an extracellular chaperone protein of constitutive expression. The Innate Immunity team of the National Institute of Health and Medical Research (INSERM) "1307-Scientific Research National Center (CNRS) 6075" unit has shown that Clu binds to extracellular histones and inhibits their inflammatory, thrombotic and cytotoxic properties. The investigators also observed (i) that in adults without severe sepsis neutropenics, low serum levels of Clu at intake and lack of normalization of rates are associated with higher mortality and (ii) Clu levels are inversely correlated with circulating histone levels. All these data suggest that Clu would have a protective role for histone-induced lesions during sepsis independently of antibiotic treatment, opening an innovative therapeutic pathway in the management of severe sepsis.
CluPPFeN is based on the hypothesis that, in a pediatric population with episodes of febrile aplasia, serum Clu and serum PTX3 levels would discriminate between febrile episodes caused by bacterial infection and other etiologies and, As a result, would reduce the consumption of antibiotics, which provide resistance, and the length of hospitalization.
Conditions
- Cancer Childhood
- Febrile Neutropenia
Interventions
- OTHER
-
Collection of blood sample
* Visit 1 : At inclusion (day 1 of chemotherapy treatment) * Visit 2 : Onset of aplasia * Visit 3a : day 1 of the 1st febrile aplasia * Visit 3b : day 3 of the 1st febrile episode * Visit 3c : day 8 of the 1st febrile episode * Visit 4a : second febrile episode (after 7 days) * Visit 4b : day 3 of the second febrile episode (after 7 days)
Sponsors & Collaborators
-
University Hospital, Angers
lead OTHER_GOV
Principal Investigators
-
Coralie MALLEBRANCHE, Dr · UH Angers
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-10
- Primary Completion
- 2024-06-13
- Completion
- 2024-08-06
Countries
- France
Study Locations
More Related Trials
-
Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis
NCT05101447 ·Status: WITHDRAWN ·Phase: PHASE2
-
Life Quality Study for PFAPA Patient
NCT02811705 ·Status: COMPLETED
-
A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen
NCT04845958 ·Status: COMPLETED
-
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
NCT06940661 ·Status: RECRUITING ·Phase: PHASE2
-
Serial Blood Count Study
NCT07066085 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen
NCT03009708 ·Status: COMPLETED ·Phase: NA
-
Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome
NCT03912129 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
NCT06666335 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
NCT06336733 ·Status: RECRUITING ·Phase: PHASE3
-
Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment
NCT04531865 ·Status: WITHDRAWN ·Phase: PHASE3
-
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
NCT02280902 ·Status: COMPLETED
-
A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
NCT07087314 ·Status: RECRUITING ·Phase: PHASE2
-
Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults
NCT05055882 ·Status: RECRUITING
-
Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
NCT00103792 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.
NCT04585152 ·Status: UNKNOWN ·Phase: PHASE2
-
FMF and Atheroscelerosis
NCT06047938 ·Status: NOT_YET_RECRUITING
-
Cortico-saving Treatments Proposed for CLIPPERS: a First Cohort
NCT01740180 ·Status: TERMINATED
-
Study of Colchicine Resistance in Familial Mediterranean Fever
NCT05418686 ·Status: COMPLETED ·Phase: NA
-
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms
NCT03688490 ·Status: COMPLETED
-
Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
NCT02862054 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
NCT03316651 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome
NCT05843968 ·Status: RECRUITING ·Phase: PHASE2
-
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
NCT03371095 ·Status: COMPLETED ·Phase: PHASE3
-
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
NCT04057703 ·Status: COMPLETED
-
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
NCT03290456 ·Status: RECRUITING ·Phase: NA